Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | Chief Financial Officer | July 01, 2024 | July 03, 2024 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Chief Financial Officer, EVP | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date July 01, 2024 · Filed July 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-07-01 · Sale · Disposed 472 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 426,595 |
Reported balance
Holding disclosure · report date 2024-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 426,595 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
LABCORP HOLDINGS INC.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,817.239 |
Ending reported balance
After 2026-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-11 · Exercise / conversion · Acquired 860 · Balance 2,062.239 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Row 2 · 2026-02-11 · Tax withholding · Disposed 245 · Balance 1,817.239 F2: Stock withholding to satisfy tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,964 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Exercise / conversion · Disposed 860 · Balance 4,964 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F2: Stock withholding to satisfy tax withholding obligations.
F3: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.
F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 18:16 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 860 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000090 · form4.xml · derivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,964 Underlying: Common Stock · 860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:16 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 245 | $289.89 | $71,023.05 |
DisclosureSEC source: 0000920148-26-000090 · form4.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,817.239 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:16 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000090 · form4.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,062.239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 20:41 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000066 · form4.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,824 Underlying: Common Stock · 2,350 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 20:41 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 7,100 | $0.00 Strike: $284.50 | $0.00 |
DisclosureSEC source: 0000920148-26-000066 · form4.xml · derivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Stock · 7,100 shares Expires 2036-02-09 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · derivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,474 Underlying: Common Stock · 893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 254 | $277.20 | $70,408.80 |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,202.239 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000036 · form4.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,456.239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 2,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004529 · form4.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 Underlying: Common Stock · 2,580 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 7,800 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004529 · form4.xml · derivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-02-10 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:00 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003711 · form4.xml · derivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,787 Underlying: Common Stock · 893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:00 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 336 | $247.74 | $83,240.64 |
DisclosureSEC source: 0001127602-25-003711 · form4.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:00 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003711 · form4.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 15:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 2,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028581 · form4.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,680 Underlying: Common Stock · 2,680 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 15:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 8,100 | $0.00 Strike: $240.63 | $0.00 |
DisclosureSEC source: 0001127602-24-028581 · form4.xml · derivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2034-12-01 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 17:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 472 | $143.90 | $67,918.68 |
DisclosureSEC source: 0001651308-24-000080 · wk-form4_1720040726.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.8513 to $144.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 17:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 899 | $155.66 | $139,938.34 |
DisclosureSEC source: 0001651308-24-000079 · wk-form4_1719437152.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 17:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 314 | $159.74 | $50,158.61 |
DisclosureSEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 5 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.12 to $159.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 17:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 253 | $159.00 | $40,226.52 |
DisclosureSEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 4 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.885 to $159.2191, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 17:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 195 | $158.58 | $30,923.94 |
DisclosureSEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.40 to $160.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 17:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 154 | $158.24 | $24,368.47 |
DisclosureSEC source: 0001651308-24-000074 · wk-form4_1718918780.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:54 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 256,659 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000056 · wk-form4_1717793661.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,659 Underlying: Ordinary Shares · 256,659 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:54 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 136,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000056 · wk-form4_1717793661.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,326 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:22 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 397 | $167.08 | $66,330.76 |
DisclosureSEC source: 0001651308-24-000016 · wk-form4_1709590911.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 17:02 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 472 | $179.55 | $84,747.36 |
DisclosureSEC source: 0001651308-23-000104 · wf-form4_168867731225214.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.5185 to $179.665, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:22 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 840 | $182.85 | $153,594.00 |
DisclosureSEC source: 0001651308-23-000102 · wf-form4_168790094090281.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 18:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 190 | $192.54 | $36,583.00 |
DisclosureSEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.50 to $192.58, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 18:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 409,058 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · derivative · entry 3 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,058 Underlying: Ordinary Shares · 409,058 shares Expires 2033-06-14 F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F5 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 18:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 107,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000091 · wf-form4_168730145579147.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,303 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 343 | $240.21 | $82,391.89 |
DisclosureSEC source: 0001651308-23-000037 · wf-form4_167788080268388.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.195 to $240.245, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 17:29 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 295 | $158.50 | $46,757.50 |
DisclosureSEC source: 0001651308-22-000119 · wf-form4_165705652132138.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| July 01, 2022 Filed Jul 18, 2022 17:22 UTC Amendment | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 317 | $158.50 | $50,244.50 |
DisclosureSEC source: 0001651308-22-000125 · wf-form4a_165817931742680.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F1 · shares: The original Form 4, filed on July 5, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on July 1, 2022 as a total of 295 American Depositary Shares ("ADSs") sold when in fact 317 ADSs were sold. As a result of this administrative error, the number of Ordinary Shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of Ordinary Shares reported as beneficially owned by the reporting person by 286 Ordinary Shares. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 17:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 589,888 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · derivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,888 Underlying: Ordinary Shares · 589,888 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 17:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 104,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,583 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 17:09 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 161 | $136.64 | $21,998.93 |
DisclosureSEC source: 0001651308-22-000084 · wf-form4_165584573671205.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 61,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000035 · wf-form4_164625910284672.xml · nonDerivative · entry 1 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,299 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F2 · balance_after: Includes 1,677 ordinary shares acquired pursuant to the Company's Second Amended and Restated 2018 Employee Share Purchase Plan. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 16:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 308 | $349.06 | $107,511.68 |
DisclosureSEC source: 0001651308-21-000147 · wf-form4_162517305797222.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.9264 to $349.35, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.